key: cord-0694502-cnqxzpr6
authors: Gasparello, Jessica; d'Aversa, Elisabetta; Breveglieri, Giulia; Borgatti, Monica; Finotti, Alessia; Gambari, Roberto
title: In vitro induction of interleukin-8 by SARS-CoV-2 Spike protein is inhibited in bronchial epithelial IB3-1 cells by a miR-93-5p agomiR
date: 2021-09-28
journal: Int Immunopharmacol
DOI: 10.1016/j.intimp.2021.108201
sha: 44997100676067def21bcc69ad8ef3b35f16db64
doc_id: 694502
cord_uid: cnqxzpr6

One of the major clinical features of COVID-19 is a hyperinflammatory state, which is characterized by high expression of cytokines (such as IL-6, IL-8 and TNF-α), chemokines and growth factors and is associated with severe forms of COVID-19. For this reason, the control of the “cytokine storm” represents a key issue in the management of COVID-19 patients. In this study we report evidence that the release of key proteins of the COVID-19 “cytokine storm” can be inhibited by mimicking the biological activity of microRNAs. The major focus of this report is on IL-8, whose expression can be modified by the employment of a molecule mimicking miR-93-5p, which is able to target the IL-8 RNA transcript and modulate its activity. The results obtained demonstrate that the production of IL-8 protein is enhanced in bronchial epithelial IB3-1 cells and that IL-8 synthesis and extracellular release can be strongly reduced using an agomiR molecule mimicking miR-93-5p.

A major new challenge for global health is the dramatic pandemic caused by the severe acute respiratory syndrome coronavirus (SARS-CoV-2), responsible of COVID-19 (Corona Virus Disease-2019) [1, 2] . The exponential increase of the number of severe COVID-19 cases and associated deaths has required awareness and proactive actions with respect to diagnosis and possible therapeutic treatments [3, 4] . Despite the fact that vaccination against SARS-CoV-2 is considered a key approach to prevent virus spread within the population and to limit the clinical manifestation of COVID-19 [5] [6] [7] , novel therapeutic protocols, drugs and management actions are urgently needed, also considering the increase of the number of SARS-CoV-2 mutants [8 -10] .

COVID-19 is characterized by two major clinical phases [11] . The first is the SARS-

and complication, such as pulmonary failure [12] [13] [14] . The second phase is a deep inflammatory state, known as "cytokine storm", caused by activation of pro-inflammatory genes, such as NF-kB, STAT-3, IL-6, IL-8, IL-1, G-CSF [15] [16] [17] [18] [19] [20] [21] [22] . The COVID-19 cytokine storm is initiated by the attachment of the SARS-CoV-2 Spike protein to the membranebound form of ACE2 (angiotensin-converting enzyme 2), followed by hyperactivation of NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells) [23, 24] . This hyperactivation of NF-κB in the lungs strongly contributes to the induction of the cytokine storm with subsequent ARDS (acute respiratory distress syndrome) [24] , frequently observed in severe COVID-19 patients. The pharmacological approaches for treating ARDS need of novel anti-inflammatory reagents and therapeutic strategies, also considering that COVID-19 patients might respond differently to anti-inflammatory treatments [25] [26] [27] [28] [29] [30] [31] [32] . The impact of anti-SARS-CoV-2 pharmacological strategies and of anti-inflammatory protocols is clear, as recently reviewed in translating IL-6 biology into effective treatments [33] .

In addition to a transcriptional regulation of the expression of pro-inflammatory genes [34, 35] , post transcriptional regulation has been also proposed, involving epigenetic changes, some of which associated with microRNAs control [36] [37] [38] [39] [40] .

MicroRNAs are short (about 20-23 nucleotides in length) non-coding RNAs that play a very important role in the post-transcriptional control of gene expression, through recognition of miRNA binding sites present in the target mRNA sequences (mainly the 3'-UTR region) [41, 42] . In this respect, we have recently shown that microRNA miR-93-5p is involved in regulation of IL-8 (interleukin-8) gene expression [43] . The IL-8 chemokine is a key mediator associated with inflammation and is deeply involved in neutrophil recruitment and degranulation [20, 35, 44] . With respect to COVID-19, IL-8 is an important player of the "cytokine storm" and, therefore, it can be considered a molecular target of anti-inflammatory therapy in the management of COVID-19 patients [30] . The direct regulation of IL-8 mRNA by miR-93-5p in IB3-1 cells was demonstrated by Fabbri et al. using a luciferase vector containing the 3′-UTR region of the IL-8 mRNA, a luciferase vector deleted of the IL-8 3′-UTR region or a vector containing an IL-8 3′-UTR region in which the miR-93-5p site was mutagenized [43] . Following this study, the involvement of miR-93-5p in regulation of IL-8 was confirmed in other reports [45] [46] [47] . This was the reason for selecting IL-8 as the major focus of our study.

The main objective of this investigation was to study if the cytokine upregulation following SARS-CoV-2 infection is associated with dysregulation of miR-93-5p. The second objective of the study was to verify whether pharmacological regulation of pro-inflammatory genes by delivery of a miR-93-5p agomiR might be considered for the development of future anti-COVID-19 therapeutic protocols. As a model system we used bronchial epithelial IB3-1 cells [48] exposed to SARS-CoV-2 Spike protein. MicroRNA levels were analyzed by RT-qPCR, while cytokine expression was analyzed by RT-qPCR and Bio-Plex analysis.

AgomiR-93-5p and control sequences were obtained by Ambion (Thermo Fischer Scientific, Waltham, Massachusetts, USA). SARS-Cov-2 Spike recombinant glycoprotein (ab49046) was purchased by Abcam (Cambridge, UK).

The IB3-1 cell line [48] was cultured in humidified atmosphere of 5% CO 2 /air in LHC-8 medium (Thermo Fischer Scientific) supplemented with 5% fetal bovine serum (FBS, Biowest, Nuaillé, France) in the absence of gentamycin. To verify the effect on proliferation, cell growth was monitored by determining the cell number/ml using a Z2 Coulter Counter (Coulter Electronics, Hialeah, FL, USA).

SARS-CoV-2 Spike protein (139 KDa; stock concentration = 7.2 M in 9% urea, 0.32% Tris-HCl pH 7.2, 50% glycerol) was diluted in 200 µl of LHC-8 medium to achieve the final concentrations used to treat IB3-1 cells. Briefly, cells seeded at 50% of confluence, were treated with Spike protein (5-50 nM) and incubated for 30 min at 4°C, then for 30 min at 37°C, according with the protocol published by Wang et al. [49] . After this incubation, LHC-8 medium supplemented with 5% (final concentration) FBS was added to a final 500 l volume and the cultures were further incubated at 37°C and for 24h. The S-protein buffer, used at a volume corresponding to the S-protein concentrations used, was found unable to stimulate the expression of IL-8 gene in treated IB3-1 cells.

collected and analyzed using Bio-Rad CFX Manager Software Version 1.7 (Bio-Rad). The relative expression was calculated using the comparative cycle threshold method and as reference sequences snRNA U6 and hsa-let-7c were used to normalize samples [53] . control) were also run in every experimental plate to assess specificity and to rule out contamination. RT-qPCR reactions were performed in duplicate for both target and normalizer gene [50] .

Cytokines released into culture supernatants were measured using Bio-Plex Human 

In order to detect significance of the observed effects, results have been expressed as mean ± standard errors (SEM) and comparison among groups was made by using analysis of variances (ANOVA) with Dunnett's test for comparison with a single control. Statistical significance was defined as significant (p < 0.05) and highly significant (p < 0.01).

We first briefly characterized the effects of SARS-CoV-2 Spike protein on the secretome profile and IL-8 gene expression in the human bronchial epithelial IB3-1 cell line. Then, we verified the Spike-mediated effects on the microRNA miR-93-5p, known to be a key regulator of IL-8 gene expression. Finally, we verified the effects of an agomiR-93 on Spike-mediated IL-8 upregulation.

When the analysis of the secretome profile of the human bronchial epithelial IB3-1 cell line is performed, it is clearly evident that production of cytokines, chemokines and growthfactors is differential and the most abundant protein in IB3-1 supernatant is IL-8 (Fig.1A) . In this work we considered to study the 15 proteins found to display the highest concentrations: The data obtained studying IL-8 gene expression are shown in Fig.1 (B-D) . (Fig.1B) , the exposure of IB3-1 cells to S-protein was associated with an increase on IL-8 mRNA content within cells (Fig. 1C) . Observation of IL-8 up-regulation in S-protein exposed IB3-1 cells was highly reproducible, as shown by analyzing the data obtained by 5 different independent experiments and analyzing the extent of the S-protein mediated increase (pg/ml) of released IL-8 protein ( Fig. 1D ; p = 0.0014) and the fold induction of IL-8 mRNA ( Figure 1E ; p = 0.0087). Moreover, the effects of SARS-CoV-2 S-protein on IL-8 expression were confirmed in other cell lines, such as the A549 [55] and Calu-3 [56] cell lines ( Supplementary Fig.S2 ).

Furthermore, when RT-qPCR analysis using -actin as internal control was compared with those obtained using as internal control GAPDH and RPL13A sequences, similar results were obtained ( Supplementary Fig.S3A ).

Since no comprehensive information is available in the literature on possible effects of SARS-CoV-2 on microRNAs, we tested whether the exposure to the Spike protein has effects on miR-93-5p. The microRNA miR-93-5p was selected in consideration of the fact that this microRNA has been firmly demonstrated to control IL-8 gene expression [43] [44] [45] [46] [47] .

Among the molecular basis of this effects, at least two mechanisms of action have been proposed and strongly supported by experimental evidences: (a) miR-93-5p can directly bind the 3'UTR sequence of the IL-8 mRNA [43] and (b) miR-93-5p suppresses Toll-like receptor 4 (TLR4), an upstream regulator of the nuclear factor NF-κB signaling pathway [57] .

This is clearly of interest, since NF-kB is a transcriptional regulator of the IL-8 gene [35] . Fig.2A shows that miR-93-5p content is reduced in IB3-1 cells exposed to 5 nM SARS-CoV-0.0218 for NF-kB p105 and p = 0.0030 for NF-kB p50) following treatment with 5 nM Sprotein. The endogenous content of -actin was analyzed as internal control.

In conclusion, increased expression of IL-8 (analyzed by Bio-Plex assay and RT-qPCR) is accompanied to a decreased production of miR-93-5p and an increased expression of the IL-8 gene regulator NF-kB in IB3-1 cells exposed to SARS-CoV-2 Sprotein. With respect to IL-8 gene expression, the differential effects on IL-8 mRNA following treatment with the agomiR-93 and the antagomiR-93 were reproducibly obtained (p < 0.01) using -actin, GAPDH and RPL13A as housekeeping sequences (Supplementary Fig.S3B ).

In order to verify whether transfection with a miR-93-5p mimic leads to a decrease of SARS-CoV-2 Spike-mediated increase of IL-8 gene expression, S-protein treated IB3-1 cells were transfected with 100 nM of lipofectamine-delivered premiR-93-5p. Data presented in Fig. 4 (A and B) show that the transfection is associated with sharp inhibition of IL-8 extracellular release (Fig. 4A) and that this is well in agreement with the miR-93-5p mediated inhibition of the S-protein induced increase of IL-8 mRNA, analyzed by RT-qPCR. When data obtained after transfection of IB3-1 cells with the agomiR-93 and the negative control are compared, it can be observed a significant differential effect, i.e. the inhibition of the Sprotein induced increase of IL-8 release (Fig. 4A ) and IL-8 mRNA content (Fig. 4B) . These data were found to be highly significant (p < 0.01), while no significant differences were found when data concerning cells treated with the negative control are compared to paired control S-protein induced samples. Interestingly, values of released IL-8 protein and IL-8 mRNA content found in S-protein exposed cells, agomiR-93-5p treated IB3-1 cells (unlike cells treated with the negative control molecule) approached values found in untreated control IB3-1 unexposed to SARS-CoV-2 S-protein.

As expected, when the results obtained when the effects on IL-8 mRNA of the agomiR-found using -actin, GAPDH and RPL13A as housekeeping sequences ( Supplementary   Fig.3C ).

proteins.

In order to verify whether transfection with a miR-93-5p mimic (premiR-93-5p) leads to a decrease of other secretomic proteins, we analyzed the Bio-Plex data focusing on the 15 secretomic proteins displaying high expression level in IB3-1 cells (see Fig. 1A ). As depicted in Fig. 3D , exposure to SARS-CoV-2 Spike protein was associated with a sharp increase of release of IL-6, IL-8, C-CSF and GM-CSF (fold > 1.5), a moderate increase of IL-9, MIP-1

(fold between 1.25 and 1.5) and no significant increase for the remaining secreted proteins (Fig. 3D) . Interestingly the proteins found to be induced by the SARS-CoV-2 S-proteins are all known to participate the "cytokine storm". Moreover, in S-protein exposed IB3-1 cells transfected with agomiR-93-5p, reduction of IL-6, IL-8, G-CSF and GM-CSF was found (Fig.   3E ). Interestingly, this is in agreement with the miR-93-5p INDEX of IL-6, IL-8, G-CSF and GM-CSF, discussed in panel C of Fig. 2 .

The potential targeting or mimicking of microRNAs has been proposed as a possible therapeutic strategy for SARS-CoV-2 infection and COVID-19 management [58] [59] [60] [61] [62] [63] . Direct targeting of SARS-CoV-2 miRNA binding sites might be proposed [59, 64] ; alternatively, the retrieval of miRNA levels which are deeply altered by SARS-CoV-2 infection might be considered [59] ; a further strategy is to employ miRNA therapeutics to modify the expression of cellular mRNA relevant in the COVID-19 clinical features [65] [66] [67] [68] [69] [70] [71] . In this respect, COVID-19 is characterized, in addition to the SARS-CoV-2 viral infection of target cells and tissues, by a deep inflammatory state, known as "cytokine storm", caused by activation of several pro-inflammatory genes, such as NF-kB, STAT-3, IL-6, IL-8, IL-1, G-CSF [15] [16] [17] [18] [19] [20] [21] [22] .

The proposed study is a proof-of-principle that the release of key proteins of the COVID-19 "cytokine storm" [16, 18] can be strongly inhibited by mimicking the biological activity of microRNAs regulating the respective mRNAs. While the major focus of this study is on IL-8, the data obtained allow to identify miR-93-5p responsive pro-inflammatory genes, whose expression can be modified by treatment of the cells with an agomiR-93-5p.

The control of the "cytokine storm" is a major issue in the management of COVID-19

patients [16-27, 33, 72-74] . This hyperinflammatory activity is associated with severe forms of COVID-19 and poor prognosis of COVID-19 patients [75] [76] [77] [78] [79] [80] [81] [82] [83] . For instance, Del Valle et al. found that high serum IL-6, IL-8 and TNF-α levels at the time of hospitalization are strong and independent predictors of patient survival. In this study, a rapid multiplex cytokine assay was implemented in order to measure serum IL-6, IL-8, TNF-α and IL-1β in a large cohort of hospitalized COVID-19 patients (n = 1,484) [26] . It was found that high serum IL-6, IL-8

and TNF-α levels at the time of hospitalization were strong and independent predictors of patient survival. In respect to IL-8, survival curves based on each cytokine measured, after multiple variable adjustments for sex, age, race/ethnicity, smoking, CKD (Chronic Kidney Disease), hypertension, asthma and CHF (Congestive Heart Failure) sustained the concept that high IL-8 serum levels are associated with low survival probability. These and similar observations sustain the hypothesis that, anti-inflammatory compounds and protocols are highly needed [84] .

Concerning this issue, targeting IL-8 has been proposed in several studies as well as in clinical trials [84] [85] [86] [87] [88] . For instance, NCT04347226 ("Anti-Interleukin-8 (Anti-IL-8) for

Patients With COVID-19") [89] , is aimed at verifying whether neutralizing IL-8 with the anti- Since the control of the "cytokine storm" is a major issue in the management of COVID-19 patients [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] , our study could stimulate research activity that can contribute to the development of protocols useful to control hyperinflammatory state associated with SARS-CoV-2 infection. Interestingly, despite the fact that our study was focused on IL-8, the agomiR-93-5p was found to inhibit also the release of IL-6, IL-8, G-CSF and GM-CSF, all of them participating to the cytokine storm. This finding should stimulate further studies on these proteins, all of them potential targets of agomiR-93-5p activity (in agreement the miR- Fig. 3C ). In addition, the possible effects of the agomiR-93-5p on the TRL4/NF-kB network should be in the future studied, considering that the TLR4/NF-kB signaling pathway is a potential target for treatment of critical stage of COVID-19 patients [91] [92] [93] .

A possible limit of the present study is the fact that (a) only one cell line was studied;

(b) no effects of the agomiR-93-5p were found on other pro-inflammatory proteins known to be activated in the COVID-19 "cytokine storm" and (c) the combination with other agents modulating IL-8 expression has not been considered. As far as the first point, we should emphasize that we consider our study just a proof-of-principle that should be confirmed and extended by further experimental efforts. This is feasible project, since we have found that Spike exposure induces change in the expression of pro-inflammatory genes also in other cells lines, such as Calu-3 and A549 cells ( Supplementary Fig.S2 ).

Concerning the second point, we could propose to identify additional miRNAs targeting and regulating other pro-inflammatory genes activated during the COVID-19

"cytokine storm" but not responding to agomiR-93-5p inhibition. In any case, the differential response of pro-inflammatory genes to the agomiR-93-5p support the specificity of the observed effects. Finally, as found as in other experimental model systems, the combined treatments using small chemical molecules and oligonucleotides might be a reasonable approach to limit side effects and increase the biological activity. Our study might contribute to these forthcoming projects.

Conceived and designed the experiments:

Roberto Gambari, Alessia Finotti, Monica Borgatti;

Performed the experiments: Jessica Gasparello, Giulia Breveglieri, Elisabetta D'Aversa;

Statistical analysis: Jessica Gasparello.

All authors read and approved the final manuscript.

Non applicable.

The data sets used and analyzed during the current study are available from the corresponding author on reasonable request.

This work is funded by the MUR-FISR COVID-miRNAPNA Project (FISR2020IP_04128). 

Clinical features of patients infected with 2019 novel coronavirus in

Clinical and immunological features of severe and moderate coronavirus disease 2019

A novel coronavirus outbreak of global health concern

System dynamics analysis of COVID-19 prevention and control strategies

COVID-19 Vaccine: A comprehensive status report

The 2020 race towards SARS-CoV-2 specific vaccines

Ongoing Clinical Trials of Vaccines to Fight against COVID-19 Pandemic

The challenge of emerging SARS-CoV-2 mutants to vaccine development

COVID-19 diagnosis and management: a comprehensive review

Lung transplantation for patients with severe COVID-19

Clinical Manifestation and Disease Progression in COVID-19 Infection

Outcomes of mechanically ventilated patients with COVID-19 associated respiratory failure

COVID-19: consider cytokine storm syndromes and immunosuppression

COVID-19 cytokine storm: The anger of inflammation

COVID-19: A new virus, but a familiar receptor and cytokine release syndrome

Serum Cytokine and Chemokine profile in Relation to the Severity of Coronavirus disease 2019 (COVID-19) in China

Therapeutic blockade of granulocyte macrophage colonystimulating factor in COVID-19-associated hyperinflammation: challenges and opportunities

G-CSF and IL-8 but not GM-CSF correlate with severity of pulmonary neutrophilia in acute respiratory distress syndrome

Potential Role of Anti-interleukin (IL)-6 Drugs in the Treatment of COVID-19: Rationale, Clinical Evidence and Risks

Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment

Deciphering the COVID-19 cytokine storm: Systematic review and meta-analysis

How COVID-19 induces cytokine storm with high mortality

Cytokine storm in COVID-19 and parthenolide: preclinical evidence

An inflammatory cytokine signature helps predict COVID-19 severity and death

Statins: Could an old friend help the fight against COVID-19?

Review on the potential action mechanisms of Chinese medicines in treating Coronavirus Disease 2019 (COVID-19)

Anti-malarial drug, artemisinin and its derivatives for the treatment of respiratory diseases

Liu Shen capsule shows antiviral and anti-inflammatory abilities against novel coronavirus SARS-CoV-2 via suppression of NF-κB signaling pathway

Silibinin and SARS-CoV-2: Dual Targeting of Host Cytokine Storm and Virus Replication Machinery for Clinical Management of COVID-19 Patients

Lung under attack by COVID-19-induced cytokine storm: pathogenic mechanisms and therapeutic implications

Translating IL-6 biology into effective treatments

Induction of IL-6 gene expression in a CF bronchial epithelial cell line by Pseudomonas aeruginosa is dependent on transcription factors belonging to the Sp1 superfamily

Mapping the transcriptional machinery of the IL-8 gene in human bronchial epithelial cells

Small RNA and transcriptome sequencing reveal the role of miR-199a-3p in inflammatory processes in cystic fibrosis airways

overexpression in cystic fibrosis airway epithelial cells decreases interleukin-8 production

Elevated miR-155 promotes inflammation in cystic fibrosis by driving hyperexpression of interleukin-8

MicroRNAs and Osteoarthritis

The role of cigarette smoke-induced epigenetic alterations in inflammation

MicroRNAs: small RNAs with a big role in gene regulation

MicroRNA functions in animal development and human disease

Expression of microRNA-93 and Interleukin-8

during Pseudomonas aeruginosa-mediated induction of proinflammatory responses

Essential involvement of interleukin-8 (IL-8) in acute inflammation

MicroRNA-93 acts as an "anti-inflammatory tumor suppressor" in glioblastoma

Regulation of IL-8 gene expression in gliomas by microRNA miR-93

Circular RNA 0039411 Is Involved in Neodymium Oxide-induced Inflammation and Antiproliferation in a Human Bronchial Epithelial Cell Line via Sponging miR-93-5p

A cystic fibrosis bronchial epithelial cell line: immortalization by adeno-12-SV40 infection

Up-regulation of IL-6 and TNF-alpha induced by SARS-coronavirus spike protein in murine macrophages via NF-kappaB pathway

BCL11A mRNA Targeting by miR-210: A Possible Network Regulating γ-Globin Gene Expression

High Levels of Apoptosis Are Induced in the Human Colon Cancer HT-29 Cell Line by Co-Administration of Sulforaphane and a Peptide Nucleic Acid Targeting miR-15b-5p, Nucleic Acid Ther

High levels of apoptosis are induced in human glioma cell lines by coadministration of peptide nucleic acids targeting miR-221 and miR-222

Efficient Delivery of MicroRNA and AntimiRNA Molecules Using an Argininocalix[4]arene Macrocycle

Comparative effects between electronic and cigarette smoke in human keratinocytes and epithelial lung cells

SARS-CoV-2 induces transcriptional signatures in human lung epithelial cells that promote lung fibrosis

Differential Signaling and Virus Production in Calu-3 Cells and Vero Cells upon SARS-CoV-2 Infection

MicroRNA-93 contributes to the suppression of lung inflammatory responses in LPS-induced acute lung injury in mice via the TLR4/MyD88/NF-kappaB signaling pathway

Farzaneh, miRNAs; a novel strategy for the treatment of COVID-19

The potential use of microRNAs as a therapeutic strategy for SARS-CoV-2 infection

COVID-19: fighting the invisible enemy with microRNAs

A new approach for COVID-19 treatment by micro-RNA

Farzaneh, miRNAs; a novel strategy for the treatment of COVID-19

miRCOVID-19: Potential Targets of Human miRNAs in SARS-CoV-2 for RNA-Based Drug Discovery

Silico and In Vitro Analyses Validate Human MicroRNAs Targeting the SARS-CoV-2 3'-UTR

Innate-Immune Defense and the Efficacy of SARS-CoV-2 Infection-A Commentary

Expression in Human Endothelial Cells: Key Implications for COVID-19

SARS-CoV-2 Spike Targets USP33-IRF9 Axis via Exosomal miR-148a to Activate Human Microglia

Targets the Transmembrane Glycoprotein Neuropilin-1 in Human Brain Microvascular Endothelial Cells

Viral MicroRNAs Encoded by Nucleocapsid Gene of SARS-CoV-2 Are Detected during Infection, and Targeting Metabolic Pathways in Host Cells

Role of endothelial miR-24 in COVID-19 cerebrovascular events

Polyphenols Could Prevent SARS-CoV-2 Infection by Modulating the Expression of miRNAs in the Host Cells

The interplay between inflammatory pathways and COVID-19: A critical review on pathogenesis and therapeutic options

Biomimetic Nanoparticles Potentiate the Anti-Inflammatory Properties of Dexamethasone and Reduce the Cytokine Storm Syndrome: An Additional Weapon against COVID-19?

The efficacy of IL-6 inhibitor Tocilizumab in reducing severe COVID-19 mortality: a systematic review

IP-10 and MCP-1 as biomarkers associated with disease severity of COVID-19

A digital protein microarray for COVID-19 cytokine storm monitoring

Increased inflammatory markers correlate with liver damage and predict severe COVID-19: a systematic review and metaanalysis

Broncho-alveolar inflammation in COVID-19 patients: a correlation with clinical outcome

Age-severity matched cytokine profiling reveals specific signatures in Covid-19 patients

Immune characteristics distinguish patients with severe disease associated with SARS-CoV-2

Inflammatory phenotyping predicts clinical outcome in COVID-19

Cytokine profile and disease severity in patients with COVID-19

Cytokine prediction of mortality in COVID19 patients

Coronavirus disease 2019: investigational therapies in the prevention and treatment of hyperinflammation

Unique immunological profile in patients with COVID-19

Small molecule therapeutics for COVID-19: repurposing of inhaled furosemide

Characterization of the Inflammatory Response to Severe COVID

A Precision Medicine Approach to SARS-CoV-2 Pandemic Management

Anti-Interleukin-8 (Anti-IL-8) for Patients With COVID-19

Phase I trial of HuMax-IL8

BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors

COVID-19 and Toll-Like Receptor

CoV-2 May Bind and Activate TLR4 to Increase ACE2 Expression, Facilitating Entry and Causing Hyperinflammation

TLR4 as a therapeutic target for respiratory and neurological complications of SARS-CoV-2

NF-κB Pathway as a Potential Target for Treatment of Critical Stage COVID-19 Patients

Effects of SARS-CoV-2 Spike protein on miR-93-5p content and NF-kB p105/p50

RNA was isolated and miR-93-5p content quantified by RT-qPCR. (B,C) Proteins were purified from IB3-1 cells treated as described in (A), and Western blotting performed (see the Methods section) using antibodies recognizing NF-kB p105/p50 and -actin. (B) Representative results indicating S-protein mediated upregulation of NF-kB; (C) quantitative analysis. The relative expression (average values ± SD) of NF-kB p105

 An agomiRNA mimicking miR-93-5p down regulates Spike-induced IL-8 gene expression

 Delivery of miR-93-5p agomiRs might be an anti-COVID-19 therapeutic strategy. AUTHOR STATEMENT Conceived and designed the experiments

Performed the experiments: Jessica Gasparello, Giulia Breveglieri

Statistical analysis: Jessica Gasparello

All authors read and approved the final manuscript

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.